We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Measurement Predicts Risk of Rapid Progression of Chronic Kidney Disease

By LabMedica International staff writers
Posted on 27 Feb 2024
Print article
Image: A simple method can predict risk of worsening of widespread kidney disease (Photo courtesy of 123RF)
Image: A simple method can predict risk of worsening of widespread kidney disease (Photo courtesy of 123RF)

Chronic kidney disease (CKD) is increasingly becoming a major health issue worldwide. For those diagnosed with CKD, the rate of disease progression can vary, with some individuals experiencing a rapid deterioration in kidney function. Healthcare providers need to spot patients who are newly diagnosed with CKD and are at a heightened risk of rapid disease progression. Early identification can allow for timely interventions that could slow down, or in some cases, prevent the progression of the disease. Now, researchers have made a breakthrough by discovering a simple method to identify individuals at high risk for rapid CKD progression, an advancement that could greatly enhance prevention and treatment strategies.

In a comprehensive study, a team of researchers from Aarhus University (Aarhus, Denmark) examined the precise risk of rapid CKD progression utilizing data from Danish health registers. This study provides valuable insights for medical professionals on identifying patients who are more likely to experience a rapid deterioration of their kidney health. The study’s findings revealed that patients who have been recently diagnosed with mild to moderate CKD face a 15% chance of rapid disease progression within three years, a situation that could lead to severe cardiovascular issues or even be life-threatening. Interestingly, the study also uncovered considerable variation in the progression risk among different patients. A simple urine test to measure protein levels emerged as a key predictor of kidney disease trajectory.

For women who do not have diabetes, elevated blood pressure/cardiovascular disease, and lack albumin in their urine, the risk of rapid CKD progression stands at 7%. Conversely, the risk escalates to 47% for men who have both diabetes and elevated blood pressure/cardiovascular disease, along with the presence of albumin in their urine. This finding is critical as albumin can act as a marker for kidney disease progression. It enables the identification of patients who are most susceptible to rapid disease deterioration, thereby aiding in the prevention of complications and potentially enhancing the patient's quality of life. This finding highlights the importance of the widespread adoption of this simple urine test. By doing so, healthcare professionals can more effectively tailor treatments and monitoring for those at the greatest risk. This approach holds the potential for substantial benefits for patients globally.

"We hope that this result can contribute to increased awareness of the importance of using readily available markers – including albumin in the urine – to identify patients at high risk of rapid progression," said Christian Fynbo Christiansen, Professor at the Department of Clinical Medicine at Aarhus University. "I think we will focus much more in the future on patients with milder stages of the disease, like those we included in this study. If we get better at preventing and treating chronic kidney disease and its associated complications, it could potentially benefit both patients and society."

Related Links:
Aarhus University

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.